<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090490</url>
  </required_header>
  <id_info>
    <org_study_id>ADARFEP_10Y</org_study_id>
    <nct_id>NCT03090490</nct_id>
  </id_info>
  <brief_title>10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals</brief_title>
  <acronym>ADARFEP_10Y</acronym>
  <official_title>Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-episode Non-affective Psychosis Individuals: a 10-year Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Marques de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro de Investigación Biomédica en Red de Salud Mental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Marques de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, non-randomized, prospective study will evaluate the risk of symptoms
      recurrence during the ten years after antipsychotic discontinuation in a sample of
      functionally recovered first-episode patients with schizophrenia spectrum disorder.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>At 10 years</time_frame>
    <description>The percentage of relapse/exacerbation in the two groups of patients, discontinuation and maintenance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in general psychopathology measured by BPRS</measure>
    <time_frame>At 10 years</time_frame>
    <description>Measured by changes in total score of the Brief Psychiatric Rating Scale (BPRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall clinical status measured by CGI</measure>
    <time_frame>At 10 years</time_frame>
    <description>Measured by changes in total score of the Clinical Global Impression (CGI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in negative symptoms measured by SANS</measure>
    <time_frame>At 10 years</time_frame>
    <description>Measured by changes in total score of the Scale for the Assessment of Negative Symptoms (SANS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in negative symptoms measured by SAPS</measure>
    <time_frame>At 10 years</time_frame>
    <description>Measured by changes in total score of the Scale for the Assessment of Positive Symptoms (SAPS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>At 10 years</time_frame>
    <description>Time to relapse in the two groups of patients, discontinuation and maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality status measured by DAS</measure>
    <time_frame>At 10 years</time_frame>
    <description>Measured by changes in total score of the Disability Assessment Scale (DAS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophrenia Relapse</condition>
  <condition>Schizophrenia Spectrum and Other Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antipsychotic treatment discontinuation (DT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance antipsychotic treatment (MT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antipsychotic treatment discontinuation</intervention_name>
    <description>Withdrawal of antipsychotic medication to stabilized patients</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maintenance treatment discontinuation</intervention_name>
    <description>Maintenance antipsychotic medication to stabilized patients</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the
             University Hospital Marqués de Valdecilla (Santander, Spain).

          -  A minimum of 18 months on antipsychotic treatment.

          -  Meeting clinical remission criteria for at least the 12 months prior to inclusion.

          -  Meeting the functional recovery criteria for at least the 6 months prior to inclusion.

          -  Stabilized at the lowest effective doses for at least the 3 months prior to inclusion.

        Exclusion Criteria:

          -  Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
             criteria for drug dependence.

          -  Meeting DSM-IV criteria for mental retardation.

          -  Having a history of neurological disease or head injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedicto Crespo-Facorro, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Marques de Valdecilla</investigator_affiliation>
    <investigator_full_name>Benedicto Crespo-Facorro</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Schizophrenia Spectrum and Other Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

